Received: 10 January 2018
Accepted: 10 August 2018
First Online: 10 October 2018
Ethics approval and consent to participate
: The research and development department at the Royal Free Hospital, where this project was undertaken, considers this study a service evaluation, with no requirement for formal ethics approval and consent to participate. All patient data were fully anonymized and archived according to the local data protection guidelines. The study described conformed to the ethical guidelines of the 1975 Declaration of Helsinki. This study was conducted and reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.
: Not applicable.
: RJ has ongoing research collaboration with Yaqrit and Takeda Pharmaceutical Company Ltd. RJ is also inventor of a drug, <scp>l</scp>-ornithine phenylacetate (OCR-002), which University College London has licensed to Ocera Therapeutics. RJ is also the founder of University College London spin-off companies Yaqrit Ltd. and CYBERLIVER Ltd. CE has an ongoing research collaboration with Sequana Medical, Merz Pharma, and Novartis. CE has received speaker’s fees from Novartis, Gilead Sciences, and Merz Pharma and was a member of the advisory board for Chiesi Farmaceutici. RPM has an ongoing research collaboration with Yaqrit. NZ recieved funding support from Welcome Trust. All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.